{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001357","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2023-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.138577+00:00","generated_at":"2026-06-11T04:38:40.085401+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Agenus cuts workforce 25%, pauses non-core programs to focus on BOT/BAL","bullets":["Workforce reduction of ~25% expected to save $2.8M by year-end; severance cost ~$1.4M.","Total savings of ~$40M by end of 2023 from halting non-BOT/BAL preclinical and clinical programs.","Partner-funded programs unaffected; first BOT/BAL regulatory filing targeted in 2024.","Restructuring supports sped-up registration and commercialization of lead immunotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001357","json":"https://secwatch.observer/filing/0001157523-23-001357.json","markdown":"https://secwatch.observer/filing/0001157523-23-001357.md","text":"https://secwatch.observer/filing/0001157523-23-001357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000115752323001357/0001157523-23-001357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000115752323001357/a53543827.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T04:38:40.085401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bf1658b57ccb5e1b1cd61f798fe3a47efa9665d","claim":"AGENUS INC announced a restructuring with charges of approximately $1.4 million affecting Agenus Inc. (excluding its independently operating subsidiaries) (approximately 25%).","evidence_excerpt":"As part of this effort, Agenus Inc. (excluding its independently operating subsidiaries) is reducing its workforce by approximately 25%, which the company expects to result in savings of approximately $2.8 million by year-end, after accounting for the cost of the workforce reduction of approximately $1.4 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000115752323001357/0001157523-23-001357-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.4 million"},{"label":"Affected area","value":"Agenus Inc. (excluding its independently operating subsidiaries)"},{"label":"Headcount","value":"approximately 25%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}